-
Alkermes Lags Q2 Earnings Estimates
24 Jul 2024 19:21 GMT
Alkermes ALKS came out with quarterly …
Alkermes, which belongs to the Zacks Medical - Biomedical and Genetics … #39;s Next for Alkermes?
While Alkermes has underperformed the market … the estimate revisions trend for Alkermes: mixed. While the magnitude …
-
Immunocytokines Market Recovery and Impact Analysis Report – Alkermes Plc, AstraZeneca Plc, CytImmune Sciences
22 Jun 2022 15:49 GMT
… . Furthermore, new technological advancements in genetic sequencing techniques are playing an … the report are as follows:
Alkermes Plc, AstraZeneca Plc, CytImmune Sciences, Cytune … was accepted by the FDA. ALKS 3831 is a drug candidate …
-
Bipolar Depression Market to Exhibit Positive Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - NeuroRx, SAGE, Janssen, COMPASS Pathways, Sunovion, AbbVie, Intas, Alkermes
03 Jul 2023 17:00 GMT
… Many factors, including genetic or hereditary alterations, changes … OLZ/SAM: Alkermes, Inc.
ALKS 3831: Alkermes, Inc.
Learn … data at the genetic and behavioral levels … Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, …
-
Opioid Use Disorder Market Therapeutic Survey Reviews, Analysis 2020 | Indivior PLC (INVVY), Alkermes plc (ALKS), Titan Pharmaceuticals, Inc. (TTNP)
13 Feb 2020 23:06 GMT
… Key Players: Indivior PLC (INVVY), Alkermes plc (ALKS), Titan Pharmaceuticals, Inc. (TTNP), Hikma … a combination of environmental and genetic factors influence the patient. Spread …
-
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov 2021 14:09 GMT
… Latter's Antipsychotic Drugs
Alkermes plc (NASDAQ: ALKS) announced that it received … ) (before the market open)
Applied Genetic Technologies Corporation (NASDAQ: AGTC) (before … : FGEN) (after the close)
Fulgent Genetics, Inc. (NASDAQ: FLGT) (after the …
-
Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants Program
23 Jul 2021 14:32 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients … Trials and Understanding Biomarkers and Genetic Mutations. Designed for patients, … 47;/www.alkermes.com/responsibility. About Alkermes plc
Alkermes plc is a fully …
-
The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO
04 Oct 2020 14:57 GMT
… -6
Chardan Virtual 4th Annual Genetic Medicines Conference: Oct. 5-6 … Advisory Committee will review Alkermes Plc's (NASDAQ: ALKS) NDA for olanzapine …
-
Alkermes: Schizophrenia Drug Producer Taking Market Share, 5.5% 3-Month Upside
28 Sep 2020 22:02 GMT
Graphic Source: Alkermes plc Introduction: What is Alkermes plc? Alkermes plc (ALKS) is a global biopharmaceutical company … therapeutic areas, including neuroscience, oncology, genetic diseases, neurodegenerative diseases, amongst others …
-
Global Antipsychotic Drugs Market Size, Share, And Growth Analysis For 2024-2033
15 Oct 2024 01:30 GMT
… as stress levels, societal pressures, genetic predisposition, biochemical imbalances, neurodevelopmental issues … Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc.
What Are The Emerging Trends …
-
Wall Street Breakfast Podcast: DOJ Weighs Google Breakup
09 Oct 2024 11:36 GMT
… events include Myriad Genetics'; (MYGN) investor meeting, Alkermes' (ALKS) event to review …
About
© 1995-2025